[Featured Stock] Eoflow Soars on News of 'Eopatch' Clinical Trial Completion
[Asia Economy Reporter Geum Bo-ryeong] Eoflow surged on news that it has completed clinical trials for the country's first wearable insulin patch pump.
At 3:12 PM on the 3rd, Eoflow's stock price recorded 51,000 won, up 12.58% (5,600 won) compared to the previous trading day.
Eoflow announced on the same day that it had completed clinical trials for the 'Eopatch.' Eopatch is the country's first wearable insulin patch pump. From December last year to July this year, Samsung Seoul Hospital and Asan Medical Center conducted a study on type 1 diabetes patients, comparing 4 weeks before and 4 weeks after wearing the Eopatch to evaluate its safety and efficacy.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Tragedy Strikes on Part-time Job Commute... Man in His 30s Arrested for Drunk Driving Death of Freshman College Student
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Eoflow stated, "The clinical trial results showed that Eopatch was effective in managing blood glucose levels for diabetics who have difficulty controlling their blood sugar."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
